DIPAITE
Pazopanib Tablets
Approved for the first-line treatment of patients with advanced renal cell carcinoma and for the treatment of patients with advanced renal cell carcinoma who have received cytokine therapy
Approved in China in May 2023, among the first wave of domestic generic launches
Recommended by the Chinese Society of Clinical Oncology (CSCO) Renal Cancer Guidelines as a first-line standard of care for advanced renal cancer.
Demonstrates better tolerability in Chinese patients, positioning pazopanib as a more suitable targeted therapy for renal cancer in China
Hexvix®
Hexaminolevulinate Hydrochloride Solution for Intravesical Administration
The world’s only approved imaging agent for assisting in the diagnosis and surgery of bladder cancer
Approved in over 30 countries and recommended by multiple international and domestic guidelines for diagnosing NMIBC (non–muscle-invasive bladder cancer)
Included in the 2022 edition of the Boao Lecheng Global Special Drug Insurance Directory
Received NMPA drug registration certificate in November 2024, seven months ahead of schedule